Marina S. Lebedkina

Marina S. Lebedkina

Auto-generated profile, based on publicly available information

Marina S. Lebedkina

Moscow Research and Clinical Center of Allergy and Immunology, Moscow Healthcare Department City Clinical Hospital Moscow Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
EKEmek Kocatürk
Emek Kocatürk
PSPascale Salameh
Pascale Salameh
RARiccardo Asero
Riccardo Asero
Mojca Bizjak-SuranMojca Bizjak-Suran
Mojca Bizjak-Suran
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
PKPavel Kolkhir
Pavel Kolkhir
Background: Chronic spontaneous urticaria (CSU), a disease predominantly affecting females, has limited information available on its differences between females and males of varying ages. Objectives: To investigate sex differences in age groups regarding disease activity, comorbidities, quality of life (QoL) and treatment patterns in CSU patients. Methods: We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria. Patients were recruited via an online platform using a standardized questionnaire. The data were analysed for demographics, age of onset, duration of urticaria, (Urticaria Activity Score [UAS], Urticaria Control Test [UCT], Chronic Urticaria Quality of Life Questionnaire [CU‐Q2oL]), family history, systemic symptoms, aggravating factors, comorbidities, smoking and alcohol consumption, laboratory parameters, burden of disease, treatment distribution and response rates, compliance to treatment and adverse events. Comparisons were made among age groups 65 years. Results: Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female. Statistically significant female predominance started at age 31 (<0.001). Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%; p < 0.001), systemic symptoms (34.6 vs. 25.4%; p < 0.001), sleep disturbance (38.9 vs. 32.5%; p < 0.001), QoL impairment (CU‐Q2oL score 32 vs. 27.7; p < 0.001) and lower rates of urticaria control than males in all medication categories ( p < 0.05 for all). Females had more concomitant diseases, including asthma, thyroid disease, obesity, autoimmune disease, gastrointestinal disease and depression ( p < 0.05 for all). The disease was especially more burdensome and refractory in females aged 51–65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits ( p < 0.05 for all). However, these differences were not prominent in the elderly females (>65 years). Conclusions: Compared with males, female CSU patients experience more burdensome disease, which gets worse in midlife. Clinicaltrials.gov (or equivalent) listing (if applicable None).

30 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MLMarina Lebedkina
Marina Lebedkina
EKElena Kovalkova
Elena Kovalkova
GAGerelma Andrenova
Gerelma Andrenova
ADAlexander Dushkin
Alexander Dushkin
ACAnton Chernov
Anton Chernov
DFDaria Fomina
Daria Fomina
Background: Chronic inducible urticaria (CIndU) is characterized by wheals and/or angioedema (AE) for 6 weeks or more in response to specific and definite triggers. Individual patients can have more than one type of CIndU. Reports on this come from single cases or small case series, most epidemiological studies did not assess whether these urticaria are standalone or mixed.Objective: Determine the features of mixed CIndU and how they differ from standalone forms.Methods: In a prospective cohort study we performed provocative testing in 210 patients with CIndU. A total of 188 patients were included (125 with the standalone CIndU and 63 with the mixed CIndU. Within each group, patients were divided into subgroups: symptomatic dermographism (SD), cold (ColdU) and cholinergic urticaria (CholU).Results: Mixed CIndU most commonly were SD+ColdU (n=19, 30.2%), SD+CholU (n=15, 23.8%), SD+DPU (n=12, 19%) and ColdU+CholU (n=9, 14.3%). Comorbid chronic spontaneous urticaria (CSU) (50.8% vs 20.8, p<0.001) and AE (36.5% vs. 20%, p=0.014) were more common in patients with mixed CIndUs. In patients with mixed CIndUs, their onset time is more closely linked to each other (n=43; 68.2%) as compared to that of comorbid CSU (12 of 32, 37.5%). MixedSD patients are younger, show earlier onset of disease and have higher rates of AE and lower rates of atopic dermatitis (AtD), as compared to patients with standalone SD. MixedColdU patients have higher rates of comorbid CSU and lower rates of AtD, higher levels of total IgE and eosinophils. MixedCholU patients are older, have a high rate of comorbid CSU, a lower incidence of allergic disease.Conclusion: This study shows for the first time that each combinations of mixed CIndU represent a distinct phenotype with its own features. These phenotypes require special attention of specialists.

7 October 2022 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
DFDaria S. Fomina
Daria S. Fomina
NMNatalya P. Maltseva
Natalya P. Maltseva
SSSofia A. Serdotetskova
Sofia A. Serdotetskova
IDInna V. Danilycheva
Inna V. Danilycheva
MLMarina S. Lebedkina
Marina S. Lebedkina
МИМихайлова Валерия Игоревна
Михайлова Валерия Игоревна
BACKGROUND: Chronic inducible urticaria is a group of diseases that is characterized by the development of wheals, angioedema, or both in response to specific triggers for 6 weeks. According to global scientific international literature, the occurrence of chronic inducible urticaria is 0.5% in the general population and approximately 20%30% in all chronic urticarias. The prevalence of chronic inducible urticaria has no statistical data in the Russian Federation. AIM: This study aimed to evaluate the region-specific epidemiology of different forms of chronic inducible urticaria. MATERIALS AND METHODS: The analysis is based on the number of unique cases extracted from the medical care records in the adults segment of the digital platform United medical information and analytical system (UMIAS) (outpatient forms) in Moscow from 2017 to 2021, including keyword search. RESULTS: This study indicated that the prevalence of chronic inducible urticaria in Moscow is correlated with published global epidemiological data. Among patients with chronic inducible urticarial, females predominate (74.2%), and the median age was 43.8 years (37 years in males and 46.4 in females). The most common form in all verified cases of chronic inducible urticaria is symptomatic dermographism (11.12%), followed by contact urticaria (5.36%), cholinergic urticaria (2.28%), cold urticaria (1.92%), delayed pressure urticaria (0.36%), vibratory urticaria (0.11%), aquagenic urticaria (0.1%), and heat urticaria (0.08%). Chronic inducible urticaria rates in Moscow are high, which increase as in global practice. This research has limitations, including the lack of ubiquitous implementation of standard protocols of provocation testing in outpatient units and the low percentage of using validated questionnaires in the routine management of patients with chronic inducible urticaria. CONCLUSIONS: Further studies dedicated to this topic are greatly necessary to answer a wide spectrum of questions, including the diagnosis process and evaluation of the severity of chronic inducible urticaria, comorbid conditions, and optimization of the treatment protocols adapted for the particular phenotype.

24 February 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ARA A Roppelt
A A Roppelt
MLM S Lebedkina
M S Lebedkina
ACA A Chernov
A A Chernov
TKT S Kruglova
T S Kruglova
OMO A Mukhina
O A Mukhina
DFD S Fomina
D S Fomina
Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/or death in COVID-19. Passive immunization with long-acting monoclonal antibodies (MABs) to SARS-CoV-2 should be considered as pre-exposure prophylaxis in patients with PIDs. Tixagevimab/cilgavimab is a combination of MABs that bind to the SARS-CoV-2 spike protein. Aim. To evaluate the efficacy and safety of pre-exposure prophylaxis of new SARS-CoV-2 infection in PIDs with the combination of tixagevimab/cilgavimab. Materials and methods. Forty eight patients diagnosed with PIDs were included in the study. Median follow-up after drug administration was 174 days. The total number of confirmed coronavirus infections in patients with PIDs as well as 6 months before and after administration of MAT were assessed. Results. In the analyzed cohort, the overall incidence of COVID-19 from pandemic onset to MABs administration was 75% (36/48), with 31% (11/36) of over-infected patients having had the infection more than once. The incidence of COVID-19 immediately 6 months before the introduction of tixagevimab/cilgavimab was 40%. All patients who had COVID-19 after pre-exposure prophylaxis had a mild infection. The incidence of COVID-19 6 months after tixagevimab/cilgavimab administration significantly decreased compared to the incidence 6 months before administration (7 and 40%, respectively; p0.001). Conclusion. The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.

6 April 2023 in Russian Journal of Allergy
Verified
Journal Article
Closed access
PDF file
SSSerdotetskova Serdotetskova
Serdotetskova Serdotetskova
САСердотецкова Софья Александровна
Сердотецкова Софья Александровна
IDInna V. Danilychevа
Inna V. Danilychevа
ДВДанилычева Инна Владимировна
Данилычева Инна Владимировна
DFDaria S. Fomina
Daria S. Fomina
VKVera G. Kalugina
Vera G. Kalugina
Chronic-induced urticaria is a group of diseases characterized by the occurrence of itchy wheals and/or angioedema in response to specific triggers, such as mechanical irritation, exposure to high and low temperatures, vibration, and ultraviolet radiation of various spectra, appearing for 6 weeks. This group of diseases is characterized by a long duration, a significant effect on the patients quality of life, and the risk of severe life-threatening reactions. The diagnosis of induced urticaria and patient-safe reproduction of symptoms by exposure to a trigger (temperature, mechanical, etc.). Currently, no medical devices have been registered in the Russian Federation for the threshold diagnosis of most physical forms of urticaria. Consequently, diagnosing and dynamic monitoring the state of these patients and their response to treatment are challenging. The question of therapy for chronic-induced urticaria also remains open due to the insufficient effectiveness of the recommended and available treatment methods. This article provides a review of current literature data. This article provides a review of current literature data.

15 March 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
DFDaria S. Fomina
Daria S. Fomina
OMOlga A. Mukhina
Olga A. Mukhina
MLMarina S. Lebedkina
Marina S. Lebedkina
MGMirada K. Gadzhieva
Mirada K. Gadzhieva
EBElena N. Bobrikova
Elena N. Bobrikova
БСБелевский Андрей Станиславович
Белевский Андрей Станиславович
Introduction. Guidelines on Biological Therapy for Bronchial Asthma of the European Academy of Allergy and Clinical Immunology (EAACI) identified a number of controversial issues for additional outcome analysis using randomized clinical trials and data from routine clinical practice. In particular, there is unmet need to clarify algorithms for prescribing biologicals using predictors of response and its timing, taking into account risk factors and multimorbidity. Omalizumab is a recombinant humanized monoclonal anti-IgE antibody of IgG1 class used for the treatment of severe refractory atopic bronchial asthma (BA) and a variety of IgE-mediated diseases. Among biological agents, this "pioneer molecule" has the greatest experience in the "allergology and immunology" profile. Detailed description of the "nonresponders" portraits will allow to perform the therapy response assessment on time and facilitate rational planning of individual therapy, which is a prerequisite for biologicals era. Using only routine methods, it is possible to perform initial and dynamic screening to phenotype a heterogeneous cohort of patients with severe asthma and chose the optimal strategy. Aim. To identify predictors of nonresponse to omalizumab anti-IgE therapy in patients with severe atopic BA and to establish optimal timing of efficacy assessment using retrospective analysis of data from the Biologic Therapy Registry of Allergology and Immunology in routine clinical practice. Materials and methods. A retrospective single-center registry study was conducted at the Allergy and Immunology Reference Center from June 2017 to August 2021. 135 patients with severe BA, with confirmed perennial sensitization, who received omalizumab according to the recommendations of the current version of GINA, were selected from the clinical and dynamic observational system (registry). Dosing regimen and administration frequency of omalizumab were determined in accordance with the instructions for the drug. Assessment of therapy efficacy was performed at the time point 4, 6 and 12 months. Patients were subgrouped into "responders" and "non-responders" according to the following criteria: ACT score less than 19 and/or difference between initial ACT score in dynamics less than 3 points; forced expiratory volume in the first second less than 80%; combination of these two criteria. Nonparametric methods of descriptive statistics were used in data processing: median, interquartile range. Differences were considered significant at p0.05. MannWhitney U-test, KruskalWallis one-way analysis of variance, and Fisher's 2 test were used to compare quantitative characteristics. Results. Heterogeneous subgroups of patients differing in reaching the criteria of "non-responders" to treatment were identified; the informativity of modifiable and unmodifiable factors differed at time-points of dynamic observation. In the differential analysis, two profiles of "nonresponders" were defined in combination with the most significant predictors of "nonrsponse" to omalizumab. According to the data obtained, one of the clinical phenotypes, namely the combination of severe asthma with the Samters triad, corresponded to the characteristics of the patient "nonresponders": age of onset is about 30 years, females, severe exacerbations of BA while taking non-steroidal anti-inflammatory drugs, accompanied with high levels of eosinophilia. Conclusion. The data obtained illustrates the hypothesis of pathogenetic heterogeneity of severe BA with the phenomenon of overlapping phenotypes and can serve as an additional orienteer for creating the individual plan of anti-IgE therapy in real clinical practice.